TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

计划入组 125 人 · 首次发布于 2025 年 10 月 31 日

A Non-interventional Cohort Safety Study of Patients With hATTR-PN

计划入组 202 人 · 首次发布于 2021 年 4 月 20 日

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

计划入组 72 人 · 首次发布于 2020 年 10 月 23 日

Transthyretin Amyloidosis Therapy (HuidaGene)

TTR gene therapy (transthyretin amyloidosis)

Vutrisiran(Amvuttra)

The Trustee for Weigh Less With Jess Trust

Australia

NATIONAL REHABILITATION CENTER FOR PERSONS WITH DISABILITIES HOSPITAL

Japan

Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University)

China

EU Approves WAINZUA (Eplontersen) for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

FDA Lifts Clinical Hold on Intellia's CRISPR Gene Therapy for Rare Nerve Disease

CHMP Backs Novel Therapies: Onpattro for hATTR and Symkevi for Cystic Fibrosis